Select Language

HLA-A*0301 & B2M & KRASG12C (VVGACGVGK)

HLA-A*0301 & B2M & KRASG12C (VVGACGVGK) Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag & Avi Tag (1)
Conjugate
Biotin-labeled (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
HLC-H82E6	Human	HEK293	Biotinylated Human HLA-A*03:01&B2M&KRASG12C (VVGACGVGK) Complex Protein (Monomer, MALS verified)

Total: 1

HLA-A*0301 & B2M & KRASG12C (VVGACGVGK) Background

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Biotinylated Human HLA-A*0301 KRASG12C (VVGACGVGK) complex protein is a complex of HLA-A*0301 of the MHC Class I, B2M, and VVGACGVGK peptide of the KRASG12C.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
ACC-006	ACC-006	Phase 2 Clinical	Jiangsu Aidea Pharmaceutical Co Ltd, China Pharmaceutical University	Solid tumours; Carcinoma, Non-Small-Cell Lung	Details
Sulforadex	SFX-01	Phase 2 Clinical	Evgen Pharma, Lalilab, Pharmagra Labs Inc	Autistic Disorder; Thrombosis; Precancerous Conditions; Ventricular Dysfunction, Left; Subarachnoid Hemorrhage; Lung Neoplasms; Renal Insufficiency, Chronic; Parkinson Disease; Asthma; Hyperplasia; Prostatic Neoplasms; Carcinoma in Situ; Breast Neoplasms; Head and Neck Neoplasms; Small Cell Lung Carcinoma; Kidney Diseases; Heart Diseases; Neoplasms; Neurodevelopmental Disorders; Nasolabial fold wrinkles; Schizophrenia; Anaplasia; Squamous Cell Carcinoma of Head and Neck; Autism Spectrum Disorder; Drug-Related Side Effects and Adverse Reactions; Heart Failure, Diastolic	Details
NLM-001	NLM-001	Phase 2 Clinical	Nelum Corp	Carcinoma, Pancreatic Ductal	Details
IMP5471-CA		Phase 1 Clinical	Shanghai Impact Pharmaceutical Co Ltd	Hematologic Diseases	Details